Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos


WASHINGTON — In the phase 1 APOLLO study, a short interfering RNA therapy lowered lipoprotein(a) by a maximum of more than 90% in certain doses, researchers reported at the American College of Cardiology Scientific Session.The agent, SLN360 (Silence Therapeutics), is one of several in development to reduce Lp(a), elevated levels of which are a major CVD risk factor and are not effectively